Records containing: Metastatic Melanoma
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2026-03-05Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma (CURB-Melanoma) - a Phase 2 Clinical Trial
-
CLINICAL_TRIALS study record update · 2026-03-02Phase 2 Study of Avapritinib in Patients With CKIT or PDGFRA Mutation-Positive Malignant Solid Tumors
-
CLINICAL_TRIALS study record update · 2026-03-02IFN-Gamma Expression in Tumor Tissue and Blood as a Predictor of Response to Immune Checkpoint Inhibitors in the First-Line Treatment of Metastatic Melanoma
-
CLINICAL_TRIALS study record update · 2026-02-20Efficacy of Immunotherapy in the First-Line Treatment of Metastatic Melanoma in Slovenia and Predictive Value of PD-L1 Expression in Tumor and Blood
-
CLINICAL_TRIALS study record update · 2026-02-18DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2026-02-18DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
-
CLINICAL_TRIALS study record update · 2026-02-17Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
-
CLINICAL_TRIALS study record update · 2026-02-17Efficacy of Immunotherapy in the First Line of Treatment of Diffuse Melanoma in Slovenia and Recognition of Prognostic and Predictive Biomarkers From Primary Tumor, Faeces and Body Fluids
-
CLINICAL_TRIALS study record update · 2026-02-13A Phase 1 Study of Nilotinib in Combination With Dabrafenib and Trametinib or Encorafenib/Binimetinib in BRAF V600 Mutant Metastatic Melanoma After Progression on BRAF/MEK Inhibition
-
CLINICAL_TRIALS study record update · 2026-02-12Knight Cancer Institute Study of Histology-Agnostic Immunotherapy With Focus on Timing: - Knight SHIFT - A Prospective, Multi-Histology Pragmatic Study
-
CLINICAL_TRIALS study record update · 2026-02-09A Phase 1-2 Dose-escalation and Expansion Study of ST101 in Patients With Advanced Unresectable and Metastatic Solid Tumors
-
CLINICAL_TRIALS study record update · 2026-02-04A Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) for Patients With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
-
CLINICAL_TRIALS study record update · 2026-01-30Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy
-
CLINICAL_TRIALS study record update · 2026-01-29UCDCC#272: A Phase I/II Study of Intralesional IL-2, Hypofractionated Radiotherapy, and Pembrolizumab in Patients Refractory to Standard-of-Care PD-1/PD-L1 Checkpoint Blockade
-
CLINICAL_TRIALS study record update · 2026-01-28Phase I Trial to Evaluate the Safety and Efficacy of Intratumoral and Intravenous Injection of Vesicular Stomatitis Virus Expressing Human Interferon Beta and Tyrosinase Related Protein 1 (VSV-IFNb-TYRP1) in Patients With Metastatic Ocular Melanoma and Previously Treated Patients With Unresectable Stage III/IV Cutaneous Melanoma
-
CLINICAL_TRIALS study record update · 2026-01-23The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma
-
CLINICAL_TRIALS study record update · 2026-01-21Molecular Characterization of Advanced Stage Melanoma by Blood Sampling
-
CLINICAL_TRIALS study record update · 2026-01-20Phase I Study of Pembrolizumab in Combination With Ibrutinib in the Treatment of Unresectable or Metastatic Melanoma
-
CLINICAL_TRIALS study record update · 2026-01-15A Phase Ib, Open-label Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of IN10018 as Monotherapy and Combination Therapy in Subjects With Metastatic Melanoma
-
CLINICAL_TRIALS study record update · 2026-01-12Long-term Safety Outcomes in Patients Treated With Replimune Oncolytic Immunotherapy Products
-
CLINICAL_TRIALS study record update · 2026-01-12A Phase I/II Study of Ex-Vivo Expanded Allogeneic Universal Donor (UD) TGFbi NK Cell Infusions in Combination With Temozolomide as a Lymphodepleting Agent in Patients With Melanoma Metastatic to the Brain
-
CLINICAL_TRIALS study record update · 2026-01-12A Prospective Non Interventional Study on Targeted Therapy for Patients With Unresectable or Metastatic BRAFV600E Mutant Melanoma
-
CLINICAL_TRIALS study record update · 2026-01-09A Phase II Study of Open Label Low Dose Ipilimumab in Combination With Pembrolizumab in Metastatic Melanoma Patients With Brain Metastases
-
CLINICAL_TRIALS study record update · 2026-01-08A Phase II Study of PD-1 Blockade With or Without LAG-3 Inhibition in Combination With Infliximab for the Treatment of Metastatic Melanoma and Prevention of Adverse Events
-
CLINICAL_TRIALS study record update · 2026-01-07A Phase I Study of In Situ Immunomodulation With CDX-301, Radiotherapy, CDX-1140, and Poly-ICLC in Patients With Unresectable and Metastatic Solid Tumors With Injectable Palpable Disease